Incretin Therapies in Obesity-related HFpEF

The central hypothesis to be tested is that patients with obesity and heart failure with preserved ejection fraction (HFpEF) prescribed tirzepatide will demonstrate reductions in measured plasma volume. In conjunction with state-of-the-art body composition analysis and measures of adipokines, this will establish an important mechanism of clinical benefit and inform disease pathophysiology. To accomplish this, this study will perform a 15-month prospective cohort study in 50 patients with obesity and HFpEF who clinically qualify for treatment with tirzepatide. The investigators will serially measure plasma volume and body composition with quantitative magnetic resonance to determine changes over time with tirzepatide treatment.

NCT Number	NCT07554638
Lead Sponsor	Columbia University
Conditions	Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Obesity
Enrollment	50 participants
Start Date	2026-06
Primary Completion	2029-04 (estimated)
Study Completion	2030-04 (estimated)
Updated on ClinicalTrials.gov	2026-05-04